Information  X 
Enter a valid email address

Company Name matching 'Bavarian Nordic A/S'

Date
Time Source
Company
Announcement
19 Jan 2022 8:13 am GNW   Bavarian Nordic A/S Bavarian Nordic Appoints Russell Thirsk as new Chief Operating Officer
06 Dec 2021 10:36 pm GNW   Bavarian Nordic A/S Bavarian Nordic A/S Announces Completion of Directed Issue of 6,373,680 New Ordinary Shares
  4:07 pm GNW   Bavarian Nordic A/S Bavarian Nordic A/S Launches Offering of up to 6,373,680 New Shares in a Directed Issue
  6:37 am GNW   Bavarian Nordic A/S Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base
05 Dec 2021 5:21 pm GNW   Bavarian Nordic A/S Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
12 Nov 2021 6:38 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Nine Months of 2021
05 Nov 2021 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Host Third Quarter 2021 Results Conference Call
24 Sep 2021 9:40 am GNW   Bavarian Nordic A/S Bavarian Nordic’s COVID-19 Funding Agreement with the Danish Ministry of Health Receives Final Approval from Parliament
01 Sep 2021 7:01 am GNW   Bavarian Nordic A/S Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate
25 Aug 2021 6:53 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces First Half 2021 Results
23 Aug 2021 12:45 pm GNW   Bavarian Nordic A/S Bavarian Nordic Receives Funding from the Danish Ministry of Health to Advance the Development of COVID-19 Booster Vaccine
  6:00 am GNW   Bavarian Nordic A/S Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine
18 Aug 2021 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Host First Half 2021 Results Conference Call and Webcast
09 Aug 2021 6:00 am GNW   Bavarian Nordic A/S Bavarian Nordic Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine
11 Jun 2021 6:12 pm GNW   Bavarian Nordic A/S Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox
07 Jun 2021 7:10 am GNW   Bavarian Nordic A/S Updated Recommendations from the World Health Organization Further Support Use of Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic
27 May 2021 6:43 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Three Months of 2021
  6:15 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B® Hepatitis B Vaccine in Germany
17 May 2021 6:30 am GNW   Bavarian Nordic A/S Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic Supports World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
07 May 2021 6:30 am GNW   Bavarian Nordic A/S U.S. Government Exercises Option for Supply of Additional Smallpox Vaccines from Bavarian Nordic
29 Apr 2021 7:09 am GNW   Bavarian Nordic A/S Bavarian Nordic Reports New Preclinical Data for COVID-19 Vaccine Confirming Potential for Broad Protection against SARS-CoV2 Variants
06 Apr 2021 10:17 am GNW   Bavarian Nordic A/S Bavarian Nordic Receives Order to Manufacture Additional Ebola Vaccines
22 Mar 2021 6:00 am GNW   Bavarian Nordic A/S Bavarian Nordic Receives Additional Smallpox Vaccine Order from the Canadian Government
12 Mar 2021 7:02 am GNW   Bavarian Nordic A/S Bavarian Nordic Publishes Annual Report 2020
09 Mar 2021 11:06 pm GNW   Bavarian Nordic A/S Bavarian Nordic A/S Announces Completion of Directed Issue and Private Placement of 5,150,000 New Ordinary Shares
  4:06 pm GNW   Bavarian Nordic A/S Bavarian Nordic A/S Seeks to Strengthen its Capital Base and Commits to Ambitious Strategy on Promising COVID-19 Vaccine Candidate
  4:05 pm GNW   Bavarian Nordic A/S Bavarian Nordic Reports 2021 Financial Guidance
08 Mar 2021 6:00 am GNW   Bavarian Nordic A/S Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial
05 Mar 2021 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Host Full Year 2020 Results Conference Call
28 Jan 2021 12:19 pm GNW   Bavarian Nordic A/S Bavarian Nordic Reports Preliminary Financial Results for 2020
05 Jan 2021 6:30 am GNW   Bavarian Nordic A/S Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries
18 Dec 2020 1:20 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma
16 Dec 2020 7:51 pm GNW   Bavarian Nordic A/S Bavarian Nordic Secures Second Part of Smallpox Vaccine Order from the U.S. Government
16 Nov 2020 8:38 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Major Shareholder Notification from Invesco Ltd.
12 Nov 2020 7:00 am GNW   Bavarian Nordic A/S Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox Viruses
11 Nov 2020 6:38 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Nine Months of 2020
26 Aug 2020 6:49 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces First Half 2020 Results
24 Aug 2020 8:22 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Smallpox Vaccine
19 Aug 2020 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Host First Half 2020 Results Conference Call
22 Jul 2020 7:00 am GNW   Bavarian Nordic A/S Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
01 Jul 2020 2:23 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces European Marketing Authorization for Ebola Vaccine
18 Jun 2020 6:08 am GNW   Bavarian Nordic A/S Bavarian Nordic and Valneva Announce Marketing and Distribution Partnership
12 Jun 2020 6:10 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen
08 Jun 2020 6:00 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine
29 May 2020 11:42 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces that Janssen has Received Positive CHMP Opinion for its Investigational Preventative Ebola Vaccine Regimen
14 May 2020 6:34 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Three Months of 2020
07 May 2020 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Host First Quarter 2020 Results Conference Call
06 May 2020 7:00 am GNW   Bavarian Nordic A/S Bavarian Nordic Enters Agreement with AdaptVac to Advance COVID-19 Vaccine Program
30 Apr 2020 5:46 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces a New Order for JYNNEOS Smallpox Vaccine from the U.S. Government Potentially Worth USD 200 Million
30 Mar 2020 12:00 pm GNW   Bavarian Nordic A/S Bavarian Nordic Updates its Financial Calendar for 2020
24 Feb 2020 4:30 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Present at Cowen and Company’s 40th Annual Health Care Conference
20 Feb 2020 6:46 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Annual Report 2019
31 Dec 2019 11:14 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Closing of Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline and Updates Year-end Cash Preparedness
17 Dec 2019 6:36 pm GNW   Bavarian Nordic A/S Bavarian Nordic Announces the Sale of Priority Review Voucher
13 Dec 2019 9:26 am GNW   Bavarian Nordic A/S Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline
15 Nov 2019 1:00 pm GNW   Bavarian Nordic A/S Bavarian Nordic to Present at Jefferies 2019 London Healthcare Conference
13 Nov 2019 6:30 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial Officer
07 Nov 2019 11:03 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen
  6:44 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces Interim Results for the First Nine Months of 2019
21 Oct 2019 7:59 am GNW   Bavarian Nordic A/S Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline


Company Announcements Archive »


a d v e r t i s e m e n t